Uncategorized
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2020 Net Sales
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2020. Preliminary and unaudited total net sales for the fourth quarter of 2020 are expected to be approximately $73 million, consisting of approximately $58 mi